Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trials without systematic review methodology.
PubMed 41562957 · doi:10.3390/medicines13010001
What was done
This narrative review evaluated published clinical trial data on three modern oral testosterone undecanoate formulations (Jatenzo, Tlando, and Kyzatrex) for the treatment of symptomatic male hypogonadism, comparing pharmacology, efficacy, safety, dosing schedules, and clinical utility.
What was found
Clinical trial data indicated that these formulations restored eugonadal testosterone levels in 80% to 88% of patients. Shared adverse effects reported were hypertension, polycythemia, and lipid changes. Practical clinical differences included a fixed-dose regimen for Tlando, titratability with direct self-pay access for Kyzatrex, and titratability supported by established trial data for Jatenzo.
Why it matters
These formulations provide needle-free oral alternatives to intramuscular and transdermal testosterone therapy without the hepatotoxicity associated with older oral androgens.
Limits
As a narrative review, it lacks systematic search methodology, meta-analytic pooling, and direct head-to-head randomized trial comparisons among the three agents. The abstract does not report total sample size, trial durations, or specific incidence rates for adverse events.
Cited by
- supports Oral formulations Tlando, Jatenzo, and Kyzatrex deliver testosterone undecanoate via lymphatic absorption without requiring 17-alpha-alkylation, avoiding the classic first-pass hepatotoxicity of older oral androgens.